KETOCONAZOLE TO REDUCE THE NEED FOR CYCLOSPORINE AFTER CARDIAC TRANSPLANTATION

被引:115
|
作者
KEOGH, A [1 ]
SPRATT, P [1 ]
MCCOSKER, G [1 ]
MACDONALD, P [1 ]
MUNDY, J [1 ]
KAAN, A [1 ]
机构
[1] ST VINCENTS HOSP,VICTOR CHANG RES INST,DARLINGHURST,NSW 2010,AUSTRALIA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 1995年 / 333卷 / 10期
关键词
D O I
10.1056/NEJM199509073331004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Because ketoconazole can markedly reduce the need for cyclosporine and because it also has antimicrobial properties, it may offer benefits in the treatment of patients after cardiac transplantation. Methods. We randomly assigned 43 patients at the time of cardiac transplantation to receive ketoconazole (200 mg per day) (23 patients) or no ketoconazole (20 patients). The main end points were the dose of cyclosporine required and the incidence of cardiac rejection and infection. Results. Ketoconazole reduced the dose of cyclosporine needed to maintain target levels by 62 percent at one week and by 80 percent at one year. The cost savings per patient (in U.S. dollars, inclusive of the cost of ketoconazole) was about $5,200 in the first year and about $3,920 in each subsequent year. The mean (+/-SD) rate of rejection in the first month was lower in the ketoconazole group than in the controls (4.2+/-0.8 vs. 5.7+/-1.0 episodes per 100 patient-days, P<0.001), and the average number of days to the first rejection was higher (30+/-29 vs. 15+/-8, P=0.03). In the first year, 22 percent of the ketoconazole group required cytolytic therapy, as compared with 35 percent of the controls, and 9 percent of the ketoconazole group required total lymphoid irradiation, as compared with 15 percent of the controls (P=0.07). The incidence of infection was lower in ketoconazole-treated patients than in controls in the second month (1.4+/-0.5 vs. 2.8+/-0.7 episodes per 100 patient-days, P<0.001) and in the third month (0.8+/-0.3 vs. 2.3+/-0.6 episodes per 100 patient-days, P<0.001). Transient, asymptomatic cholestasis was observed in the ketoconazole group. Conclusions. After cardiac transplantation, ketoconazole greatly reduced the need for cyclosporine, resulting In substantial cost savings. Ketoconazole also reduced the rates of rejection and infection, without persistent toxic effects. We now use ketoconazole routinely in cardiac-transplant recipients.
引用
收藏
页码:628 / 633
页数:6
相关论文
共 50 条
  • [41] Cost-containment strategies in transplantation: The utility of cyclosporine-ketoconazole combination therapy
    Odocha, O
    Kelly, B
    Trimble, S
    Murigande, C
    Toussaint, RM
    Callender, CO
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (02) : 907 - 909
  • [42] Cystic Duct Biliary Tubes Reduce the Need for ERCP after Liver Transplantation.
    Chauhan, A.
    Rosen, C.
    Nyberg, S.
    Heimbach, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 257 - 258
  • [43] Cyclosporine-Related Posterior Reversible Encephalopathy Syndrome After Heart Transplantation: Should We Withdraw or Reduce Cyclosporine?: Case Reports
    Dzudie, A.
    Boissonnat, P.
    Roussoulieres, A.
    Cakmak
    Mosbah, K.
    Bejui, F. T.
    Obadia, J. F.
    Sebbag, L.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (02) : 716 - 720
  • [44] Conversion of cyclosporine to microemulsion cyclosporine in renal allograft recipients treated with cyclosporine and ketoconazole
    Videla, C
    Vega, J
    Borja, H
    Gatica, A
    Clavero, R
    Aldunate, T
    REVISTA MEDICA DE CHILE, 1997, 125 (04) : 438 - 445
  • [45] BENEFIT OF TACROLIMUS/MYCOPHENOLATE TO REDUCE CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANTATION
    Aaronson, Alistair
    Kittleson, Michelle
    Patel, Jignesh
    Rafiei, Matthew
    Osborne, Ashley
    Chang, David
    Czer, Lawrence
    Kobashigawa, Jon
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E798 - E798
  • [46] CYCLOSPORINE PHARMACOKINETICS WITH CONCOMITANT KETOCONAZOLE THERAPY
    SCHROEDER, TJ
    WEISKITTEL, P
    PESCE, AJ
    MYRE, SA
    ALEXANDER, JW
    CLINICAL CHEMISTRY, 1989, 35 (06) : 1176 - 1177
  • [47] Benefit of Tacrolimus/Myocophenolate To Reduce Cardiac Allograft Vasculopathy after Heart Transplantation
    Patel, J.
    Kittleson, M.
    Rafiei, M.
    Osborne, A.
    Aaronson, A.
    Chang, D. H.
    Azarbal, B.
    Czer, L.
    Moriguchi, J.
    Kobashigawa, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S50 - S50
  • [48] OPTIMAL DOSING OF CYCLOSPORINE AND TACROLIMUS TO IMPROVE MEDICATION ADHERENCE AND TO REDUCE DRUG COSTS AFTER HEART TRANSPLANTATION
    Barten, Markus J.
    Hua, Xiuang
    Bernhardt, Alexander
    Rybczynski, Meike
    Reichenspurner, Hermann
    TRANSPLANTATION, 2020, 104 (09) : S586 - S586
  • [50] CHANGES IN CYCLOSPORINE METABOLISM WITH COADMINISTRATION OF KETOCONAZOLE
    SCHROEDER, TJ
    MELVIN, DB
    CLARDY, CW
    WADHWA, NK
    MYRE, SA
    REISING, JM
    WOLF, RK
    COLLINS, JA
    PESCE, AJ
    FIRST, MR
    CLINICAL CHEMISTRY, 1987, 33 (06) : 979 - 979